Statement:Due to limited proficiency, errors are inevitable, and some information may not be the most up-to-date. Please feel free to leave comments pointing them out.This article only provides an introduction to drugs related to medical health, not a recommendation for treatment plans (if involved); this article does not constitute any investment advice.
On January 31, GSK announced its 2023 financial report: revenue of £30.328 billion, a year-on-year increase of 5%, with R&D investment of £6.223 billion, accounting for 21% of total revenue.
GSK's business is divided into three major segments: Specialty Medicines, Vaccines, and General Medicines.Vaccine revenue amounted to 9.826 billion pounds, increasing by 24% year-on-year. Its non-respiratory syncytial virus (RSV) vaccine, Arexvy, was approved for marketing by the FDA in May 2023, becoming the first preventive RSV vaccine.Generated revenue of £1.238 billion (approximately $1.569 billion) in 2023,At the latest exchange rate, 1 GBP ≈ 1.267 USD）, becoming GSK's "blockbuster drug."August 2023,Pfizer's RSV Vaccine Abrysvo Approved for Marketing, with 2023 Sales of $890 Million, lower than Arexvy.In addition to the RSV vaccine, GSK also has a shingles vaccine called Shingrix, which achieved sales of £3.446 billion in 2023, representing a year-on-year increase of 17%, making it the top-selling product for GSK.Looking ahead to 2024, GSK's revenue is expected to grow by 5%-7%, and its adjusted operating profit will increase by 7%-10%.
References:
GSK 2023 Financial Report
